Pages that link to "Q42804988"
Jump to navigation
Jump to search
The following pages link to Selective induction of high avidity CTL by altering the balance of signals from APC. (Q42804988):
Displaying 50 items.
- Peptide intra-tumor injection for cancer immunotherapy: enhancement of tumor cell antigenicity is a novel and attractive strategy (Q27020970) (← links)
- Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody (Q33581597) (← links)
- Investigation on correlation between expression of CD58 molecule and severity of hepatitis B (Q33866063) (← links)
- Vaccines as monotherapy and in combination therapy for prostate cancer (Q34039068) (← links)
- Memories that last forever: strategies for optimizing vaccine T-cell memory (Q34060493) (← links)
- Strategies to use immune modulators in therapeutic vaccines against cancer (Q34275601) (← links)
- Vaccines with enhanced costimulation maintain high avidity memory CTL. (Q34312218) (← links)
- Induction of higher-avidity human CTLs by vector-mediated enhanced costimulation of antigen-presenting cells (Q34312794) (← links)
- Progress on new vaccine strategies for the immunotherapy and prevention of cancer (Q34328457) (← links)
- Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status. (Q34521343) (← links)
- Rapid perturbation in viremia levels drives increases in functional avidity of HIV-specific CD8 T cells (Q34819446) (← links)
- Viral Vector-Based Therapeutic Cancer Vaccines (Q35515080) (← links)
- TRICOM: enhanced vaccines as anticancer therapy (Q35843625) (← links)
- Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa (Q35849596) (← links)
- Progress on new vaccine strategies against chronic viral infections (Q35864857) (← links)
- A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses (Q35871793) (← links)
- Therapeutic cancer vaccines: current status and moving forward (Q35894347) (← links)
- Multiple costimulatory modalities enhance CTL avidity (Q35901490) (← links)
- High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors (Q35980504) (← links)
- Development of cancer vaccines to activate cytotoxic T lymphocytes (Q36150458) (← links)
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer (Q36254081) (← links)
- Current perspectives in prostate cancer vaccines (Q36317185) (← links)
- Poxviral vectors for cancer immunotherapy (Q36350388) (← links)
- Cancer vaccines: current directions and perspectives in prostate cancer (Q36368968) (← links)
- Protective immunity against hepatitis C virus infection (Q36410459) (← links)
- Monoclonal antibodies as targeting and therapeutic agents: prospects for liver transplantation, hepatitis and hepatocellular carcinoma. (Q36478827) (← links)
- Cancer vaccines: preclinical studies and novel strategies (Q36543800) (← links)
- Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines (Q36543806) (← links)
- Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit (Q36544143) (← links)
- Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines (Q36604795) (← links)
- Roadmap to a better therapeutic tumor vaccine (Q36684496) (← links)
- PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma (Q36764939) (← links)
- Mobilizing the low-avidity T cell repertoire to kill tumors (Q36891310) (← links)
- Cutting edge: Dendritic cells prime a high avidity CTL response independent of the level of presented antigen (Q36984273) (← links)
- Taming cancer by inducing immunity via dendritic cells (Q36990604) (← links)
- CD8+ T cell efficacy in vaccination and disease (Q37184070) (← links)
- In vivo modulation of avidity in highly sensitive CD8(+) effector T cells following viral infection (Q37231728) (← links)
- Promising novel immunotherapies and combinations for prostate cancer (Q37250456) (← links)
- Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL. (Q37521861) (← links)
- CTL quality and the control of human retroviral infections (Q37543246) (← links)
- IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. (Q37589836) (← links)
- Regulation of CD4 T-cell receptor diversity by vaccine adjuvants (Q37717709) (← links)
- Cancer Immunotherapy and Nanomedicine (Q37785836) (← links)
- Mucosal Immunity and HIV-1 Infection: Applications for Mucosal AIDS Vaccine Development (Q37825810) (← links)
- Antigen sensitivity and T-cell receptor avidity as critical determinants of HIV control (Q37852548) (← links)
- Functional avidity: a measure to predict the efficacy of effector T cells? (Q38066211) (← links)
- Therapeutic cancer vaccines: a long and winding road to success (Q38162261) (← links)
- Peptide Dose and/or Structure in Vaccines as a Determinant of T Cell Responses (Q38582086) (← links)
- Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections (Q38768298) (← links)
- Identification and characterization of agonist epitopes of the MUC1-C oncoprotein. (Q39063057) (← links)